Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Finished Goods: 2024

Historic Finished Goods for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2024 value amounting to $5.2 million.

  • ARS Pharmaceuticals' Finished Goods was N/A to $7.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Finished Goods is $5.2 million.
  • ARS Pharmaceuticals' 5-year Finished Goods high stood at $5.2 million for FY2024, and its period low was $5.2 million during FY2024.
  • Moreover, its 1-year median value for Finished Goods was $5.2 million (2024), whereas its average is $5.2 million.